PURPOSE: Few data are available in correlation between bone mass density (BMD) and men with COPD This study was designed to investigate the prevalence of osteoporosis in men with COPD. with special regards to the role of glucocorticoids (GCs) use in these patients
METHODS: The study included 56 male patients with documented COPD for at least two years, their age ranged 24-66 years. Subjects were divided into 3 groups: group 1. consisted of 18 patients, who were oral GCs users, group 2. consisted of 18 patients who were inhaled GCs users and group 3. consisted of 20 patients, never GCs users (this group was considered as the control group). All subjects underwent measurement of BMD. pulmonary function tests (PFTs) and a number of biochemical markers of bone metabolism. The associations between BMD. PFTs. GCs use. biochemical markers and clinical variables were analyzed.
RESULTS: Patients included group 1 had the lowest BMD at any site (p< 0.0001). group 2 patients had over all bone mass loss, that was indistinguishable from those who were received oral GCs. group 3 patients had less bone mass reduction than the other two groups. Of the clinical and biochemical markers measured. N-telopeptide was significantly correlated with bone mass (P<0.01), but there was no correlation with other markers. The lowest mean of FEV1 (Forced Expiratory Volume in one second) was observed in group 1 patients. BMI (Body Mass Index) was weakly correlated with bone mass in the 3 studied groups
CONCLUSIONS: Bone mass loss is a common problem in male patients with COPD. while the use of oral GCs increase the frequency of osteoporosis, inhaled GCs therapy offered no protection from bone loss.
CLINICAL IMPLICATIONS: COPD patients who had never treated with GCs had also a substantial risk for osteoporosis. We advocate early screening and preventive intervention.
DISCLOSURE: The following authors have nothing to disclose: Sherif Alsayed
No Product/Research Disclosure Information